The Union Health Ministry has allowed the use of Hydroxychloroquine in combination with Azithromycin under close monitoring for patients with severe disease and requiring ICU management as per the revised Guidelines on Clinical Management of COVID–19.
The earlier guidelines, dated March 17, which included use of Anti-HIV drugs Ritonavir-Lopinavir in high risk patients, now stand repealed.
Azithromycin is a commonly used antibiotic, while Hydroxychloroquine (HCQ) is used in treatment of autoimmune diseases such as rheumatoid arthritis. It is also used in treating malaria.
The azithromycin-hydroxychloroquine combination is part of an upcoming multi-country trial anchored by the World Health Organization to examine the efficacy of various drug combinations against COVID-19.
Source : Indian Express